Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016958 | 1.00 | SMARCA2 (0.49) | SMARCA2SMARCA4SYKVNN1LOXL2 | |
| SCHEMBL15003950 | 0.86 | SYK (0.40) | SMARCA2SMARCA4SYKVNN1LMNA | |
| SCHEMBL28019417 | 0.85 | VNN1 (0.58) | SMARCA2SMARCA4VNN1LOXL2DDR1 | |
| SCHEMBL503171 | 0.83 | KDM5C (0.55) | SMARCA2SMARCA4SYKVNN1LOXL2 | |
| SCHEMBL31085231 | 0.83 | LMNA (0.58) | SYKLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10202654 | 0.83 | LMNA (0.58) | SYKLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29427285 | 0.83 | KDM5C (0.55) | SMARCA2SMARCA4SYKVNN1LOXL2 | |
| SCHEMBL25221330 | 0.81 | VNN1 (0.46) | SMARCA2SMARCA4VNN1LOXL2DDR1 | |
| SCHEMBL29427234 | 0.81 | LOXL2 (0.49) | SMARCA2SMARCA4SYKVNN1LOXL2 | |
| SCHEMBL9444888 | 0.81 | LMNA (0.45) | SYKLMNANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356387-B1 | ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS | UNIV MONASH (AU) | 2024-06-26 | — | — | EP | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| EP-3922630-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Capella Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-02-08 | — | — | US | disclosed |
| WO-2017053537-A1 | BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | CAPELLA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2016130396-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130396-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | SMARCA2 1142/4885SMARCA4 635/4885SYK 4815/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | SMARCA2 1142/4885SMARCA4 635/4885SYK 4815/4885 |
| US-20180037568-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, DNMT1 | SMARCA2 446/4885SMARCA4 436/4885SYK 2700/4885 |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | SMARCA2 4012/4885SMARCA4 4461/4885SYK 230/4885 |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | SMARCA2 3737/4885SMARCA4 4382/4885SYK 246/4885 |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | SMARCA2 3737/4885SMARCA4 4382/4885SYK 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.